Abstract
Despite newly developed antiepileptic drugs to suppress epileptic symptoms, approximately one third of patients remain drug refractory. Consequently, there is an urgent need to develop more effective therapeutic approaches to treat epilepsy. A great deal of evidence suggests that endogenous nucleosides, such as adenosine (Ado), guanosine (Guo), inosine (Ino) and uridine (Urd), participate in the regulation of pathomechanisms of epilepsy. Adenosine and its analogues, together with non-adenosine (non-Ado) nucleosides (e.g., Guo, Ino and Urd), have shown antiseizure activity. Adenosine kinase (ADK) inhibitors, Ado uptake inhibitors and Ado-releasing implants also have beneficial effects on epileptic seizures. These results suggest that nucleosides and their analogues, in addition to other modulators of the nucleoside system, could provide a new opportunity for the treatment of different types of epilepsies. Therefore, the aim of this review article is to summarize our present knowledge about the nucleoside system as a promising target in the treatment of epilepsy.
Keywords: Epilepsy treatment, nucleosides.
Current Medicinal Chemistry
Title:The Antiepileptic Potential of Nucleosides
Volume: 21 Issue: 6
Author(s): Z. Kovacs, K.A. Kekesi, G. Juhasz and A. Dobolyi
Affiliation:
Keywords: Epilepsy treatment, nucleosides.
Abstract: Despite newly developed antiepileptic drugs to suppress epileptic symptoms, approximately one third of patients remain drug refractory. Consequently, there is an urgent need to develop more effective therapeutic approaches to treat epilepsy. A great deal of evidence suggests that endogenous nucleosides, such as adenosine (Ado), guanosine (Guo), inosine (Ino) and uridine (Urd), participate in the regulation of pathomechanisms of epilepsy. Adenosine and its analogues, together with non-adenosine (non-Ado) nucleosides (e.g., Guo, Ino and Urd), have shown antiseizure activity. Adenosine kinase (ADK) inhibitors, Ado uptake inhibitors and Ado-releasing implants also have beneficial effects on epileptic seizures. These results suggest that nucleosides and their analogues, in addition to other modulators of the nucleoside system, could provide a new opportunity for the treatment of different types of epilepsies. Therefore, the aim of this review article is to summarize our present knowledge about the nucleoside system as a promising target in the treatment of epilepsy.
Export Options
About this article
Cite this article as:
Kovacs Z., Kekesi K.A., Juhasz G. and Dobolyi A., The Antiepileptic Potential of Nucleosides, Current Medicinal Chemistry 2014; 21(6) . https://dx.doi.org/10.2174/1381612819666131119154505
DOI https://dx.doi.org/10.2174/1381612819666131119154505 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Curcumin Reduces Neuronal Loss and Inhibits the NLRP3 Inflammasome Activation in an Epileptic Rat Model
Current Neurovascular Research Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Editorial: Zebrafish Psychopharmacology
Current Psychopharmacology Drug Discovery and Design for Complex Diseases through QSAR Computational Methods
Current Pharmaceutical Design Combined Therapies for Lysosomal Storage Diseases
Current Molecular Medicine Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Ester Prodrugs of Ketoprofen: Synthesis, In Vitro Stability, In Vivo Biological Evaluation and In Silico Comparative Docking Studies Against COX-1 and COX-2
Current Drug Discovery Technologies Autoimmune Diabetes Mellitus: The Importance of Autoantibodies for Disease Prediction and Diagnostic Support
Current Immunology Reviews (Discontinued) Insights into the Molecular Mechanism of hERG1 Channel Activation and Blockade by Drugs
Current Medicinal Chemistry Drugs from the Sea: Conopeptides as Potential Therapeutics
Current Medicinal Chemistry Ifenprodil, a Novel NMDA Receptor Antagonist : Site and Mechanism of Action
Current Drug Targets Cognitive Dysfunction in Major Depressive Disorder: A State-of-the-Art Clinical Review
CNS & Neurological Disorders - Drug Targets Convection-Enhanced Delivery: Neurosurgical Issues
Current Drug Targets Imidazole: An Essential Edifice for the Identification of New Lead Compounds and Drug Development
Mini-Reviews in Medicinal Chemistry Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Antipsychotic Medication Adherence and Satisfaction Among Palestinian People with Schizophrenia
Current Clinical Pharmacology Insight into the Mechanism of the Four-Plate Test-Retest Procedure Using Etifoxine as Compared with Gabapentin
Current Psychopharmacology Potassium Channels as Targets for the Management of Pain
Central Nervous System Agents in Medicinal Chemistry A Review on Chitosan in Drug Delivery for Treatment of Neurological and Psychiatric Disorders
Current Pharmaceutical Biotechnology Application of Pharmacophore Models for the Design and Synthesis of New Anticonvulsant Drugs
Mini-Reviews in Medicinal Chemistry